As of June 17, 2025, Enzon Pharmaceuticals Inc (ENZN) reports a ROA (Return on Assets) of 1.65%.
ROA (Return on Assets) evaluates how effectively a company turns its assets into profits, showcasing resource utilization.
Historical Trend of Enzon Pharmaceuticals Inc's ROA (Return on Assets)
Over recent years, Enzon Pharmaceuticals Inc's ROA (Return on Assets) has shown significant volatility. The table below summarizes the historical values:
| Date | ROA (Return on Assets) |
|---|---|
| 2024-12-31 | 1.65% |
| 2023-12-31 | 2.88% |
| 2022-12-31 | -0.42% |
| 2021-12-31 | -1.05% |
| 2020-12-31 | -2.70% |
This slight upward trend highlights how Enzon Pharmaceuticals Inc manages its efficiency in using assets to generate earnings over time.
Comparing Enzon Pharmaceuticals Inc's ROA (Return on Assets) to Peers
To better understand Enzon Pharmaceuticals Inc's position, it's useful to compare its ROA (Return on Assets) against industry peers. Below are selected comparisons:
| Company | ROA (Return on Assets) |
|---|---|
| Enzon Pharmaceuticals Inc (ENZN) | 1.65% |
| Idera Pharmaceuticals Inc (IDRA) | 281.35% |
| Tenax Therapeutics Inc (TENX) | -18.21% |
| Inhibikase Therapeutics Inc (IKT) | -27.91% |
| Skye Bioscience Inc (SKYE) | -36.51% |
| aTyr Pharma Inc (LIFE) | -41.76% |
Compared to its competitors, Enzon Pharmaceuticals Inc's ROA (Return on Assets) is among the highest compared to peers, demonstrating superior efficiency in generating earnings from assets.